US 12,138,264 B2
Pharmaceutical compositions
Deepak B. Mundhra, Collegeville, PA (US); and Rennan Pan, King of Prussia, PA (US)
Assigned to ViiV Healthcare Company, Wilmington, DE (US)
Filed by VIIV HEALTHCARE COMPANY, Wilmington, DE (US)
Filed on May 31, 2024, as Appl. No. 18/679,621.
Application 18/679,621 is a continuation of application No. 17/547,682, filed on Dec. 10, 2021.
Application 17/547,682 is a continuation of application No. 15/292,394, filed on Oct. 13, 2016, granted, now 11,224,597, issued on Jan. 18, 2022.
Application 15/292,394 is a continuation of application No. 13/823,316, abandoned, previously published as PCT/US2011/051713, filed on Sep. 15, 2011.
Claims priority of provisional application 61/383,541, filed on Sep. 16, 2010.
Prior Publication US 2024/0307387 A1, Sep. 19, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4985 (2006.01); A61K 9/16 (2006.01); A61K 31/505 (2006.01); A61P 31/00 (2006.01); A61P 31/18 (2006.01)
CPC A61K 31/4985 (2013.01) [A61K 9/16 (2013.01); A61K 31/505 (2013.01); A61P 31/00 (2018.01); A61P 31/18 (2018.01)] 30 Claims
 
1. A parenteral pharmaceutical suspension comprising 0.1-50% by weight a compound of formula (I)

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
0.1-10% by weight polysorbate,
0.1-10% by weight polyethylene glycol 3350, 4000 or 8000,
mannitol, and
water,
wherein the suspension has mean particle size of 0.1-1 μm, and
wherein the suspension has been sterilized by gamma irradiation.